Halozyme Therapeutics, Inc. · San Diego, CA United States (NASDAQ: HALO)
| 11388 Sorrento Valley Rd. | Phone: 858-794-8889 |
| San Diego, CA | Fax: 858-704-8311 |
| 92121 | |
| United States | 
Map This Company |
Halozyme Therapeutics, Inc. Rankings
More Companies in These Related Industries: Company Description
Halozyme Therapeutics is searching for cures to the world's "ologys." The company is developing treatments for endocrinology, oncology, and dermatology. It is also creating products for the drug delivery market. Halozyme's portfolio is based on its Enhanze technology which includes the family of human enzymes called hyaluronidases. There are two marketed products using Halozyme's technology: Hylenex and Cumulase. Hylenex is used as an adjuvant for drug and fluid infusions and Cumulase is used for in-vitro fertilization. Halozyme receives limited income from sales of the active pharmaceutical ingredients to the third party that makes Cumulase, as well as revenues from its partnerships with
Halozyme Therapeutics, Inc. Reports
No subscription, no problem.
Download presentation-ready reports. From company profiles to the competitive landscape, Hoover's offers immediate access to individual reports.
Financials
| Company Type | Public - NASDAQ: HALO Headquarters |
|---|---|
| Fiscal Year-End | December |
| 2010 Employees | 102 |
Executives
28 executives listed for Halozyme Therapeutics, Inc.'s San Diego, CA location.
| Chairman | Kenneth Kelley | |
|---|---|---|
| President, CEO, and Director | Gregory Frost | |
| VP Manufacturing and Operations | William Fallon |